# AstraZeneca account plan

> AstraZeneca is a Cambridge, UK-based biopharmaceutical company with $58,739m of FY2025 Total Revenue and 96,100 employees.

## At a glance

AstraZeneca is a science-led biopharmaceutical company headquartered in Cambridge, UK, researching, developing, manufacturing and selling prescription medicines in Oncology, BioPharmaceuticals (CVRM, Respiratory & Immunology, Vaccines & Immune Therapies) and Rare Disease (Alexion). It has an active presence in more than 80 countries and sales in more than 125. FY2025 Total Revenue was $58,739m, up 9% (8% at CER), with Core Operating profit of $18,478m and Reported EPS of $6.60. It had 96,100 employees at end-2025. Its shares trade in London, Stockholm and, since 2 February 2026, directly on the NYSE; Pascal Soriot is CEO and Michel Demaré Chair.

## Business units

- **Oncology** ($25,619m FY2025 Total Revenue, 44% of Total Revenue): Cancer medicines including Tagrisso ($7,254m), Imfinzi ($6,063m), Calquence, Lynparza and Enhertu; revenue grew 15% in 2025 and 18% in H1 2026 to $14,124m. Led commercially by David Fredrickson and in R&D by Susan Galbraith.
- **BioPharmaceuticals - CVRM** ($12,861m FY2025 Total Revenue): Cardiovascular, renal and metabolism medicines led by Farxiga ($8,492m), plus Crestor, Lokelma and Wainua; Baxfendy (baxdrostat) was approved in the US in May 2026. CVRM fell 8% in H1 2026 on Farxiga's US loss of exclusivity and China volume-based procurement.
- **BioPharmaceuticals - Respiratory & Immunology** ($8,866m FY2025 Total Revenue): Respiratory and immunology medicines such as Symbicort, Fasenra, Breztri, Tezspire and Saphnelo; revenue grew 13% in 2025 and 12% in H1 2026. BioPharmaceuticals is led by Ruud Dobber (business unit) and Sharon Barr (R&D).
- **BioPharmaceuticals - Vaccines & Immune Therapies** ($1,268m FY2025 Total Revenue): Beyfortus (with Sanofi), Synagis and FluMist; revenue fell 13% in 2025.
- **Rare Disease (Alexion)** ($9,126m FY2025 Total Revenue, 16% of Total Revenue): Complement medicines Ultomiris and Soliris plus Strensiq and Koselugo; revenue grew 4% in 2025 and 13% in H1 2026 to $4,911m. Led by Marc Dunoyer.
- **Other Medicines** (2% of Total Revenue): Mature products outside the three therapy areas.

## Strategic priorities

- **Ambition 2030**: Launch at least 20 new medicines and reach $80 billion Total Revenue by 2030; 11 NMEs had been approved by July 2026.
- **Transformative technologies**: ADCs, bispecifics, cell therapy, T-cell engagers, radioconjugates and genomic medicines; 16 Phase III trials of next-generation bispecifics run across 8 tumour types.
- **Weight management and cardiovascular risk**: Five Phase III trials started for the oral GLP-1 elecoglipron, alongside baxdrostat and the oral PCSK9 laroprovstat.
- **Enterprise AI**: An Enterprise AI unit was created in December 2025; over 90% of the small-molecule discovery pipeline is AI-enabled, and a Tempus partnership builds a model to predict trial success.
- **US growth and localised supply**: The US is projected at about 50% of Total Revenue by 2030, and manufacturing is being built in the US and China so the regions can operate independently.
- **Cost and systems efficiency**: A post-Alexion restructuring with $4.0 billion expected cost targets about $2.2 billion of run-rate benefits by end-2026, and the Axial ERP project runs to 2030.

## Latest results

In H1 2026 Total Revenue was $30,672m, up 9% (6% at CER), and Q2 Total Revenue was $15,384m. Core Operating profit rose 12% to $10,510m (Core Operating Margin 34%) and Core EPS 12% to $5.21. Oncology grew 18% to $14,124m and Rare Disease 13% to $4,911m, while BioPharmaceuticals fell 1% to $11,151m as Farxiga and Brilinta lost exclusivity. Net debt rose $3,538m to $26,912m. FY2026 guidance was reconfirmed at CER: Total Revenue up a mid-to-high single-digit percentage and Core EPS up a low double-digit percentage.

## Investments and deals

- **$50 billion US programme**: Planned investment in US manufacturing and R&D, including a $4.5 billion plant in Charlottesville, Virginia and a $2 billion Maryland expansion.
- **China and Singapore**: $2.5 billion for a Beijing R&D centre and manufacturing, and a $1.5 billion ADC plant in Singapore.
- **Acquisitions and licences**: EsoBiotec (up to $1 billion), SixPeaks Bio and FibroGen China in 2025; in 2026 Zegfrovy from Dizal ($600m upfront) and TQC3721 from CTTQ ($200m upfront), plus a $1,104m upfront payment to CSPC.
- **R&D and capex**: $14.2bn invested in R&D in 2025; FY2026 capex is expected to rise by about a third from $3,270m.

## Challenges and risks

- **Loss of exclusivity**: Farxiga's US loss of exclusivity coincides with its Medicare negotiated price from 2026, and Brilinta and roxadustat are also declining; BioPharmaceuticals is described as being in a transitional period.
- **Pricing pressure**: IRA price negotiation for Farxiga and Calquence, US most-favoured-nation pricing, European generic erosion and China volume-based procurement.
- **Pipeline setbacks**: CARDIO-TTRansform (Wainua in ATTR-CM) and EMERALD-2 failed their primary endpoints in 2026.
- **Competition in China**: China revenue was flat at $3,510m in H1 2026, with intense competition in EGFR TKIs and ADCs.
- **Geopolitics, tariffs and data**: Principal risks include tariff and trade-control volatility, cybersecurity and data and AI governance.

## What leadership says

> "While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks." — Pascal Soriot, CEO, H1 and Q2 2026 results report, 27 July 2026

> "we don't need additional BD if we continue delivering as we expect to across the pipeline." — Pascal Soriot, CEO, H1 and Q2 2026 results webinar, 27 July 2026

> "Having AI tool is not sufficient. You have to have the data." — Pascal Soriot, CEO, Positive Leadership podcast, 13 March 2026

> "Our biopharmaceutical business is in a transitional period." — Ruud Dobber, EVP BioPharmaceuticals Business Unit, H1 and Q2 2026 results webinar, 27 July 2026


## Where a supplier can help

- **Plant construction and equipment**: The $50 billion US programme, the Virginia and Maryland sites and the Singapore ADC plant, with capex up about a third in 2026, need engineering, equipment and automation suppliers.
- **Data for AI in R&D**: The Enterprise AI unit and the CEO's point that AI needs data open room for data platforms, real-world data and AI infrastructure partners.
- **Clinical trial execution**: 25 key Phase III readouts over 18 months and more than 100 Phase III studies point to CRO, trial-site and patient-recruitment services.
- **ERP and efficiency programmes**: The Axial ERP project to 2030 and the restructuring programme fit systems integration and process automation services.
- **Launch support**: Launches such as Baxfendy and pre-launch work for tozorakimab create demand for commercial, market access and medical engagement services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report and Form 20-F Information 2025](https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231xex15d1.htm)

Annual report · 2026-02-24

- AstraZeneca is a global, science-led biopharmaceutical company (HQ Cambridge, UK) organised around three therapy areas: Oncology, BioPharmaceuticals (CVRM, Respiratory & Immunology, Vaccines & Immune Therapies) and Rare Disease (Alexion); 96,100 employees at end-2025, active presence in more than 80 countries and sales in more than 125.
- FY2025 Total Revenue $58,739m, up 9% (8% at CER); Product Sales $55,573m, Alliance Revenue $3,067m (up 39%), Collaboration Revenue $99m (down 89%). Reported Operating profit $13,743m (up 37%), Core Operating profit $18,478m (up 9%); Reported EPS $6.60 (up 45%), Core EPS $9.16 (up 12%).
- Revenue mix: Oncology $25.6bn (44%), BioPharmaceuticals $23.0bn (39%), Rare Disease $9.1bn (16%); by region US $25.5bn (43%), Emerging Markets $15.3bn (26%), Europe $12.7bn (22%), Established Rest of World $5.2bn (9%). China Total Revenue $6,654m (up 4%).
- 16 blockbuster medicines; biggest products Farxiga ($8,492m), Tagrisso ($7,254m), Imfinzi ($6,063m, up 29%), Ultomiris ($4,718m), Calquence ($3,518m), Lynparza ($3,279m) and Enhertu ($2,775m, up 40%).
- Ambition 2030: at least 20 new medicines and $80 billion Total Revenue by 2030 (9 NMEs delivered so far); $14.2bn invested in R&D in 2025, 197 pipeline projects, 16 positive Phase III readouts, more than 100 Phase III studies ongoing.
- US is the largest market and is projected at about 50% of Total Revenue by 2030; October 2025 agreement with the US administration on prices plus a three-year Section 232 tariff exemption; plan to invest $50 billion in US manufacturing and R&D, including a $4.5 billion plant in Virginia and a $2 billion Maryland expansion.
- Other investments: $2.5 billion in a sixth strategic R&D centre and manufacturing in Beijing, a $1.5 billion ADC plant in Singapore; acquisitions of EsoBiotec (up to $1 billion), SixPeaks Bio and FibroGen China; new Enterprise AI unit created in December 2025 (over 90% of small-molecule discovery AI-enabled).
- Shares listed directly on the NYSE from 2 February 2026 (harmonised listing in London, Stockholm and New York, approved by 99.36% of votes); FY2025 dividend $3.20 (up 3%); Net debt $23,374m.
- 2026 guidance (CER): Total Revenue up a mid-to-high single-digit percentage, Core EPS up a low double-digit percentage, Core tax rate 18-22%.
- Key risks: pipeline failure or delay, pricing/affordability pressure (IRA: Farxiga's Medicare price from 2026 coinciding with US loss of exclusivity; Calquence from 2027), supply, cybersecurity and AI/data governance, litigation and IP, geopolitical and tariff volatility.

### [AstraZeneca results: H1 and Q2 2026 (half-year financial report)](https://www.rns-pdf.londonstockexchange.com/rns/9440N_1-2026-7-26.pdf)

Interim report · 2026-07-27

- H1 2026 Total Revenue $30,672m, up 9% (6% at CER); Q2 2026 $15,384m, up 6% (5% at CER). Alliance Revenue $1,699m, up 31%.
- Core EPS $5.21, up 12% (11% at CER); Reported EPS $3.60, up 4%. Core Operating profit $10,510m, up 12% (11% at CER), Core Operating Margin 34%.
- Oncology $14,124m (46% of revenue, up 18%, 15% at CER) and Rare Disease $4,911m (16%, up 13%) offset BioPharmaceuticals $11,151m (36%, down 1%, 5% at CER), where CVRM fell 8% (12% at CER) on Farxiga's US loss of exclusivity and China volume-based procurement.
- Regions: US $12,890m (42%, up 8%), Europe $6,822m (22%, up 17%), Emerging Markets $8,319m (27%, up 8%), of which China $3,510m flat (down 5% at CER), Established RoW $2,641m.
- Pipeline: Baxfendy (baxdrostat) approved in the US for hypertension in May 2026; Etcamah (camizestrant) approved in the EU and Japan; 30 approvals in major regions since Q4 2025 results; CARDIO-TTRansform (Wainua in ATTR-CM) failed its primary endpoint; sone-ve (CLARITY-Gastric01) and Imfinzi VOLGA positive.
- Business development: Zegfrovy licensed from Dizal ($600m upfront, up to $900m milestones); TQC3721 licence from CTTQ/Sino Biopharmaceutical ($200m upfront); $1,104m upfront paid to CSPC.
- Net debt rose $3,538m to $26,912m; capex $1,513m in H1, FY2026 capex expected up about a third; interim dividend $1.06, FY2026 dividend intended at $3.30.
- FY2026 guidance reconfirmed (CER): Total Revenue up a mid-to-high single-digit percentage, Core EPS up a low double-digit percentage. 9M/Q3 results due 30 October 2026.

### [H1 and Q2 2026 results webinar for investors and analysts (transcript)](https://allmind.ai/earnings/event/2935582)

Executive talk · Pascal Soriot, Chief Executive Officer · 2026-07-27

- Soriot: H1 2026 Total Revenue grew 6%, and 11% excluding Farxiga and Brilinta (hit by generics); Core EPS up 11%; 11 NMEs approved against the target of 20 by 2030.
- The $80 billion 2030 revenue ambition is "a risk-adjusted forecast" that already assumes setbacks such as the failed CARDIO-TTRansform trial for Wainua.
- Peak sales views raised: tozorakimab (COPD) to more than $5 billion; sone-ve (CLDN18.2 gastric ADC) $3-5 billion; Wainua, Etcamah and Baxfendy each more than $5 billion; efzimfotase alfa $3-5 billion.
- Oncology grew 15% to $14.1 billion (US 18%, Europe 16%); Calquence passed $1 billion in a quarter for the first time; Zegfrovy licensed to defend EGFR lung cancer leadership.
- BioPharmaceuticals is "in a transitional period": down 5% to $11.2 billion as Farxiga, Brilinta and roxadustat lose exclusivity, offset by Fasenra, Tezspire, Breztri and Saphnelo; elecoglipron (oral GLP-1) moved into Phase III.
- 25 key Phase III readouts planned over the next 18 months; 16 Phase III trials of next-generation bispecifics across 8 tumour types.
- CFO Aradhana Sarin: capex up around a third in 2026, about $2.5 billion of milestone payments expected for the year, BD upfronts of just over $2 billion year to date; R&D at the upper end of the low 20s percentage of revenue.
- Soriot: "we don't need additional BD" to grow after 2030; the plan assumes about 60% aggregate Phase III probability of success versus a 75%-plus record. Still "very bullish" on China, both as a market and as a source of innovation.

### [How a Purpose-Led Culture Transformed AstraZeneca (with Pascal Soriot) — Positive Leadership podcast](https://www.youtube.com/watch?v=A-uMsFA9v3Q)

Podcast · Pascal Soriot, Chief Executive Officer · 2026-03-13

- Long-form Positive Leadership podcast interview of CEO Pascal Soriot by Jean-Philippe, a former AstraZeneca board member (2008-2016), published on YouTube on 13 March 2026.
- Turnaround: when he joined in 2012 AstraZeneca sold $30 billion and was forecast to fall to $17-18 billion; it stabilised at $19-20 billion, sold older products to fund R&D and focused on oncology, cardiovascular and respiratory, later adding rare disease through Alexion.
- Culture: moved the company from a "marketing era" to science and patients, with values of following the science, putting patients first and taking risks; he refused a "we will not fail in phase three" mindset.
- Pfizer bid (2014): rejected because a merger would "totally distract us" from Tagrisso and Lynparza; the share price was 29-30 when he joined and around 140 today versus an offer that ended around 55 pounds.
- R&D economics: development takes "10 plus years"; his portfolio review committee meets twice a month and never approves less than 500 million of spend per meeting.
- Oncology: "we are starting to cure some cancers", by combining IO, ADCs, T-cell engagers and cell therapy.
- Geopolitics: supply chains are being localised in the US and China; Europe risks losing "its health sovereignty" within 15 years because governments treat pharma as a cost; China is "a massive contributor to innovation".
- AI: improves probability of success; partnership with Tempus to build a multimodal model predicting trial success, but "having AI tool is not sufficient. You have to have the data."

## Questions about AstraZeneca

### What does AstraZeneca do?

AstraZeneca researches, develops, manufactures and sells prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare diseases.

### What is AstraZeneca's revenue?

FY2025 Total Revenue was $58,739m, up 9%; H1 2026 Total Revenue was $30,672m.

### How many employees does AstraZeneca have?

AstraZeneca had 96,100 employees at the end of 2025.

### Who leads AstraZeneca?

Pascal Soriot is CEO, Michel Demaré is Chair and Aradhana Sarin is CFO.

### What is AstraZeneca's strategy?

Ambition 2030 targets at least 20 new medicines and $80 billion Total Revenue by 2030, driven by transformative technologies such as ADCs and bispecifics.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
